Esperance Pharmaceuticals is a pre-clinical stage company developing lytic peptides conjugated to both antibody drug conjugates (ADCs) and Chimeric antigen receptor (CAR) T-cell therapy to make them more effective.

To learn more about the company's partnering program or to contact management, please email Hector Alila at hector@esperancepharma.com